Introduction
============

The motor symptoms in Parkinson\'s disease (PD) are primarily due to the loss of a single cell type, i.e. the dopaminergic neurons located in the *substantia nigra pars compacta* that project to the putamen and caudate nucleus. Due to the relatively restricted neuropathology, PD is considered a suitable disease for cell replacement-based therapy. Transplantation of mesencephalic tissue from human embryos, obtained from therapeutic abortions has provided proof-of-concept that PD can be treated with cell therapy (for review see Morizane et al., [@B27]). However, not all patients have improved after transplanted with embryonic mesencephalic tissue and subsets of patients have developed troubling dyskinesias (Freed et al., [@B13]; Hagell and Cenci, [@B17]; Hagell et al., [@B18]; Levivier et al., [@B26]; Olanow et al., [@B32]). Furthermore, this source of dopaminergic neurons is not readily obtainable, it is heterogeneous in cell composition and its application is inherently connected to ethical issues related to the abortion. An ideal source of cell material should be available in large quantities in a predictable manner, it should be highly enriched in midbrain dopaminergic neurons, and safe to transplant with no risks of infection or tumor growth.

Human embryonic stem cells (hESCs) derived from the inner cell mass of human blastocysts are such a potential source of cells. These cells are pluripotent and can self-renew (allowing massive expansion). It has already been demonstrated that they can generate dopaminergic neurons in culture (Ben-Hur et al., [@B2]; Brederlau et al., [@B4]; Cho et al., [@B8]; Iacovitti et al., [@B23]; Ko et al., [@B25]; Park et al., [@B34], [@B33]; Perrier et al., [@B36]; Roy et al., [@B40]; Schulz et al., [@B41]; Sonntag et al., [@B43]; Ueno et al., [@B47]; Yan et al., [@B50]; Yang et al., [@B51]; Zeng et al., [@B54]) (Table [1](#T1){ref-type="table"}). Improving the survival and functional integration of hESC-derived dopaminergic neurons after transplantation is a major challenge that has to be overcome before clinical application of hESCs is even to be considered in PD (Björklund et al., [@B3]; Correia et al., [@B9]; Deierborg et al., [@B11]; Hall et al., [@B19]; Morizane et al., [@B27]). Dopaminergic neurons derived from hESCs are functional *in vitro*, as shown by their ability to generate action potentials and release dopamine (Brederlau et al., [@B4]; Hong et al., [@B22]; Ko et al., [@B25]; Park et al., [@B33]; Perrier et al., [@B36]; Roy et al., [@B40]; Yan et al., [@B50]; Zeng et al., [@B54]). However, only a few studies have demonstrated that hESC-derived grafts can contain considerable numbers of tyrosine hydroxylase (TH)-expressing neurons and have claimed that they consistently induce behavioral improvement in the unilateral 6-hydroxydopamine (6-OHDA)-lesion rat model of PD (Cho et al., [@B8]; Ko et al., [@B25]; Roy et al., [@B40]; Yang et al., [@B51]).

###### 

**Summary of the major results of the studies published by January 2008, on the *in vitro* differentiation of hESCs into dopaminergic neurons and transplantation of hESC-derived cells in the striatum of 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson\'s disease**.

  Cell line                       *In vitro*                                                           *In vivo*                                                                                                     Reference                                                                                                                                                                                                                                                                      
  ------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------ --------------------------
  H1, H9, HES-3                   SDIA, SHH, FGF8, AA, BDNF, GDNF and TGF-β                            TuJ1+/total 30--50%. TH+/TuJ1+ 64--80%                                                                        *Study only in vitro*                                                                                                                                                                                                                                                          Perrier et al., [@B36]
  BG01                            No factors added                                                     Not mentioned TH+ colonies/total 87%                                                                          Neural precursors or differentiated cells                                                 5 weeks                    Surviving cells in all transplanted rats                                                           Very few TH+ neurons                                   Zeng et al., [@B54]
  BG01, BG03                      BDNF and GDNF                                                        Many Nestin+ and TuJ1+. TH+/TuJ1+ 75%                                                                         1,000--20,000 of differentiated cells in clumps                                           12 weeks                   Surviving cells in 75% of transplanted rats                                                        Few TH+ cells in 3/15 transplanted rats                Schulz et al., [@B41]
  HES-1                           SDIA, Noggin and bFGF                                                TH+/total 0.5%, TuJ1+/total 29%                                                                               400,000 partially dissociated spheres of Neural precursors                                12 weeks                   Surviving cells in 19/21 of transplanted rats (with 73% of implanted cells)                        From 102 to 603 TH+ cells (average 389 TH) per graft   Ben-Hur et al., [@B2]
  MB03                            bFGF and TGF-α                                                       TH+/NF+ 15%, NF+/total 78%                                                                                    *Study only in vitro*                                                                                                                                                                                                                                                          Park et al., [@B34]
  H1, H9                          FGF8, SHH, AA, BDNF, GDNF                                            TH+/total 31%, TH+/TuJ1+ 50--60%                                                                              *Study only in vitro*                                                                                                                                                                                                                                                          Yan et al., [@B50]
  HSF-6, SNU-hES-3, Miz-hES-1     SDIA, BDNF, GDNF, NT-3, SHH, FGF8                                    TH+/TuJ+ \>40%, Tuj1+/total \>95%                                                                             500,000 neural precursors or differentiated neurons                                       2 weeks                    Higher cell survival when neural precursors were transplanted                                      No TH+ neurons                                         Park et al., [@B33]
  SA002                           SDIA, bFGF                                                           TH+/TuJ+ 2% (16 days), 14% (20 days), 37% (23 days), Tuj1+/total 9% (16 days), 32% (20 days), 20% (23 days)   100,000 cells after 16, 20 and 23 days of differentiation                                 2 and 13 weeks             Surviving grafts in all transplanted rats. Higher survival with cells differentiated for 16 days   10--50 TH+ cells per graft                             Brederlau et al., [@B4]
  KhES-1                          AMED                                                                 TuJ+/total 40% TH+/TuJ+ 31%                                                                                   *Study only in vitro*                                                                                                                                                                                                                                                          Ueno et al., [@B47]
  H1, H9                          FGF2, SHH, FGF8 and secreted factors from human midbrain astrocyte   TH+/TuJ+ 67%, Tuj1+/total 40%                                                                                 500,000 cells, containing dopaminergic progenitors and mature neurons                     10 weeks                   Graft survival in all transplanted rats                                                            27,000 TH+ cells/mm^3^ of the graft                    Roy et al., [@B40]
  H7, H9                          SDIA, Wnt1, Noggin, SHH, FGF8, AA, BDNF, GDNF, TGF-β                 TH+/total 23%                                                                                                 100,000 cells, containing dopaminergic progenitors, mature neurons and undifferentiated   12 weeks                   Surviving grafts in 9/12 (H7)                                                                      Average of 160 TH+ cells (H7)                          Sonntag et al., [@B43]
  H9, BG01, HUES7, HUES8          Noggin, dbcAMP                                                       TH+ colonies/total 60% (H9), 78% (HUES7), 81% (HUES8), 56% (BG01)                                             200,000--500,000 differentiated cells                                                     2--3 weeks                 Surviving grafts in 7/10.                                                                          Detected TH+ cells                                     Iacovitti et al., [@B23]
  H9                              FGF8, SHH, AA, BDNF, GDNF                                            TH+/TuJ+ 43%                                                                                                  200,000 differentiated dopaminergic neurons                                               1 day, 1, 4 and 20 weeks   25,000 surviving cells at 1 week                                                                   1,273 TH+ cells at 20 weeks                            Yang et al., [@B51]
  HSF-6, H9                       SDIA, SHH, bFGF, AA                                                  TuJ+/total 60%, TH+/TuJ+ 34--45%                                                                              1,250,000 neural precursors                                                               8 weeks                    300,000 cells surviving cells                                                                      200 TH+ cells                                          Ko et al., [@B25]
  H1 and HSF-6                    SDIA, SHH, bFGF, EGF, AA                                             TuJ+/total 33%, TH+/TuJ+ 10%                                                                                  *Study only in vitro.*                                                                                                                                                                                                                                                         Hong et al., [@B22]
  SA002                           SDIA, FGF-20 and bFGF                                                TuJ+/total 17%, TH+/total 15%                                                                                 *Study only in vitro.*                                                                                                                                                                                                                                                         Correia et al., [@B10]
  SNUhES1, SNUhES3 and SNUhES16   BFGF, SHH, FGF-8, AA                                                 TuJ+/total 77%, TH+/TuJ+ 86%                                                                                  500,000 differentiated neurons                                                            12 weeks                   395,671 surviving cells                                                                            10,732 TH+ cells                                       Cho et al., [@B8]

AA, ascorbic acid; AMED, amniotic membrane matrix-based ES cell differentiation; BDNF, brain derived neurotrophic factor; bFGF, basic fibroblast growth factor; dbcAMP, dibutyryl cAMP; EGF, epidermal growth factor; FGF-8, fibroblast growth factor-8; FGF-20, fibroblast growth factor-20; GDNF, glial cell-derived neurotrophic factor; NF, neurofilament; NT-3, neurotrophin-3; SDIA, stromal cell-derived inducing activity; SHH, sonic hedgehog; SSEA-4, stage specific embryonic antigen-4; TGF-α, transforming growth factor-α; TGF-β, transforming growth factor-β; TH, tyrosine hydroxylase; TRA-1-60, tumour related antigen-1-60; Tuj1, ?III Tubulin; Wnt1, wingless-related MMTV integration site 1.

Previous studies suggest that approximately 100,000 surviving dopaminergic neurons are needed in the grafts on each side of the brain in a PD patient in order to obtain any clinical benefits after transplantation (Hagell and Brundin, [@B16]). For rats with unilateral 6-OHDA lesions of the nigrostriatal pathway, only 1000 dopaminergic neurons must survive for the transplants to exert a significant effect on amphetamine-induced rotation around 6 weeks after surgery (Nakao et al., [@B29]). Therefore, obtaining a large fraction of hESCs that differentiate into dopaminergic neurons *in vitro* would be an important step towards success of a cell-based therapy for PD. For this reason, we recently studied the effect of a known midbrain dopaminergic trophic factor, fibroblast growth factor (FGF)-20 (Ohmachi et al., [@B31], [@B30]), on the differentiation of hESCs into dopaminergic neurons and their subsequent survival *in vitro*. Earlier work has shown that FGF-20 increases the number of TH-expressing neurons derived from neural stem cells *in vitro* (Grothe et al., [@B15]; Takagi et al., [@B46]). Expression of this growth factor is specific to the *substantia nigra* in the rat brain (Ohmachi et al., [@B31]). In addition, the FGF-20 receptor, FGFR1c, is highly expressed by TH-positive neurons in the *substantia nigra* and is present at lower levels in other brain regions (Ohmachi et al., [@B30]). In serum-free cultures of primary rat mesencephalic tissue, FGF-20 only prevents the death of the TH-expressing cells and does not affect the total number of neurons yielded (Ohmachi et al., [@B31], [@B30]). Moreover, certain *Fgf20* gene haplotypes are associated with the increased risk of PD (van der Walt et al., [@B48]). In our recently published study we found that addition of FGF-20 during differentiation of hESCs also increases the yield of dopaminergic neurons, probably both by promoting differentiation of the stem cells and by decreasing apoptosis among the differentiated neurons (Correia et al., [@B10]).

Factors that Increase the Efficiency in the Differentiation of Hescs into Dopaminergic Neurons *In Vitro*
=========================================================================================================

Recent years have seen a dramatic number of studies describing the effects of a plethora of growth factors and feeder cells on the development of neural cells from ESCs. It is believed that ESCs differentiate into neuronal cells "by default", if not presented with stimuli that drive towards an alternative fate. These stimuli may be either soluble growth factors, or signaling elicited by cell-to-cell contact. Bone morphogenic proteins (BMPs) suppress neuronal differentiation. For this reason, addition of Noggin, a BMP antagonist, increases the commitment of hESCs to a neuronal fate during differentiation (Ben-Hur et al., [@B2]; Iacovitti et al., [@B23]; Pera et al., [@B35]; Sonntag et al., [@B43]). Two major *in vitro* systems that induce neuronal differentiation of ESCs are the formation of embryoid bodies (Carpenter et al., [@B7]; Park et al., [@B34]; Schulz et al., [@B42]; Zhang et al., [@B55]) and the co-culturing with a layer of specific feeder cells (Perrier et al., [@B36]; Roy et al., [@B40]; Zeng et al., [@B54]). In suspension cultures, ESCs spontaneously aggregate, differentiate and form spherical embryoid bodies containing precursor cells of all three germ layers (mesoderm, endoderm and neuroectoderm). By supplementing the culture medium with certain mitogenic factors, such as epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF), neural precursor cells can be expanded further. Alternatively, co-culturing of ESCs with specific feeder cells induces their differentiation into neurons. Feeder cells with such properties include: (1) mouse stromal cell line PA6, isolated from mouse skull bone (also known as MC3T3-G2) (Park et al., [@B33]; Zeng et al., [@B54]); (2) mouse stromal cell line MS5, derived from the aorta-gonad-mesonephron (Hong et al., [@B22]; Ko et al., [@B25]; Perrier et al., [@B36]; Sonntag et al., [@B43]); (3) amniotic membrane matrix (Ueno et al., [@B47]) and (4) human midbrain astrocytes (Roy et al., [@B40]). Stromal cell-derived inducing activity (SDIA) is the name given to the activity of factors produced by the stromal cells that promote neuronal differentiation of ESCs (Kawasaki et al., [@B24]), which have still not been fully identified (Hayashi et al., [@B21]; Kawasaki et al., [@B24]; Yamazoe et al., [@B49]; Zeng et al., [@B54]). In the same way, the differentiation factors produced by the amniotic membrane matrix and human midbrain astrocytes are also still not completely defined (Roy et al., [@B40]; Ueno et al., [@B47]).

Different soluble factors, which are known to be involved in the development and maintenance of the midbrain dopaminergic system *in vivo*, have been used to induce the dopaminergic differentiation of hESCs *in vitro* (see Table [1](#T1){ref-type="table"}). Sonic hedgehog (SHH) and FGF-8 are involved in the patterning of mesencephalic dopaminergic neurons (Ye et al., [@B52]). Addition of FGF-8 into a co-culture system with PA6 feeder cells genetically modified to overexpress SHH leads to a substantial increase in the number of neurons expressing TH (Park et al., [@B33]). Transforming growth factor (TGF)-α is present in early embryonic structures where midbrain dopaminergic neurons develop. This factor is believed to be essential for both induction and survival of dopaminergic neurons *in vitro* and *in vivo* (Farkas et al., [@B12]). After culturing in the presence of TGF-α for 21 days, about 15% of the hESC-derived cells become TH-positive and release dopamine (Park et al., [@B34]). Perrier and co-workers combined co-culture with addition of different soluble factors in their differentiation protocol. They co-cultured hESCs with MS5 cells overexpressing wingless-related MMTV integration site 1 (Wnt1), and the culturing medium was sequentially supplemented by combinations of the following factors SHH, FGF-8, brain-derived neurotrophic factor (BDNF), GDNF, TGF-β3, dibutyryl cAMP (dbcAMP) and ascorbic acid (AA). The sequential addition of a combination of these factors presumably imitates the development of the midbrain *in vivo*. Thereby it leads to the expression of transcription factors typical for midbrain neurons in a sequence similar to that observed during normal development. After 50 days exposure to those growth factors, over 100 TH-positive neurons could be generated from each undifferentiated hESC initially plated, which is the highest yield reported to date (Perrier et al., [@B36]).

In our own experiments, when we co-cultured hESCs with PA6 feeders in presence of 1 ng/ml FGF-20, we observed a 5-fold increase in the yield of hESC-derived TH-positive neurons (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The percentage of TH-expressing neurons among the total hESC-derived cells increased from 3% in the absence of FGF-20 to 15% in its presence (Correia et al., [@B10]). In concordance with our results, FGF-20 treatment of monkey ESCs during differentiation also resulted in a 5-fold increase (from 5% to 24%) in the percentage of TH-positive neurons within the total number of neurons (Takagi et al., [@B46]).

![**Major findings of the treatment with FGF-20 of hESCs cultures during dopaminergic differentiation by co-culturing with PA6 cells**.](fnins-02-026-g001){#F1}

![**Representative images of TH-, cleaved caspase-3- and HNuc-positive cells in 3 weeks differentiated hESCs/PA6 co-cultures untreated and treated with FGF-20 (--FGF-20 and +FGF-20, respectively, adapted from Correia et al., [@B10])**.](fnins-02-026-g002){#F2}

How Does FGF-20 Promote the Increase in the Yield of Dopaminergic Neurons from hESCs?
=====================================================================================

The underlying mechanism by which FGF-20 enhances the yield of stem cell-derived dopaminergic neurons still remains unclear (Takagi et al., [@B46]). In our study, supplementation of culture media with FGF-20 did not increase cell proliferation. However, it decreased the fraction of apoptotic cells, as detected by the presence of cleaved caspase-3 (from 2.5% without FGF −20 to 1.2% with FGF-20, out of the total hESC-derived cells, Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) (Correia et al., [@B10]). Therefore, we conclude that FGF-20 increases the yield of TH-positive neurons via increased dopaminergic differentiation and reduced apoptotic cell death. Furthermore, we did not observe an effect of FGF-20 on the percentage of cells positive for βIII-Tubulin (about 17% out of the total hESC-derived cells in both conditions, Figure [1](#F1){ref-type="fig"}), indicating that it did not increase overall neuronal differentiation.

Using immunocytochemistry (Correia et al., [@B10]) and gene expression analysis (Anisimov et al., [@B1]), we detected the presence of FGFR-1 in undifferentiated hESCs, PA6 cells and hESC-derived TH-positive neurons. This suggests that FGF-20 could act (1) on the pluripotent hESCs, promoting their differentiation into dopaminergic neurons; and/or (2) directly on hESC-derived dopaminergic neurons to increase their survival; and/or (3) on the PA6 cells, inducing them to produce factors that promote differentiation and survival of dopaminergic neurons. It has been previously suggested that FGF-20, in a different cell culture paradigm, has an indirect mode of action on dopaminergic differentiation mediated by Schwann cells (Grothe et al., [@B15]).

FGF-20 has been suggested to activate anti-apoptotic defenses in cultured rat mesencephalic dopaminergic neurons, particularly in calbindinnegative A9 dopaminergic neurons, i.e. those located in the *substantia nigra* pars compacta (Murase and McKay, [@B28]; Ohmachi et al., [@B31], [@B30]). We observed a significant difference in the number of cells positive for cleaved caspase-3 in FGF-20-supplemented cultures (1.2%), compared to untreated cultures (2.5%). Furthermore, we also observed lower numbers of cells positive for the apoptotic markers cleaved caspase-8 and Bcl2-associated X protein (BAX), when we added FGF-20 to the cultures. Cleaved caspase-8 is involved in initiating the extrinsic cell death pathway, while BAX polymerization mediates mitochondrial cytochrome C release, which initiates the intrinsic pathway (Riedl and Shi, [@B37]). We therefore hypothesize that FGF-20 inhibits apoptosis of hESC-derived cells that is triggered through both the extrinsic and intrinsic pathways. The possible effect of FGF-20 in reducing cell death through apoptosis has been suggested by a previous study from Murase and McKay. In this study it was demonstrated FGF-20 promotes Bad phosphorylation, induced by PI3K activation, and Bax downregulation, due to p53 degradation (Murase and McKay, [@B28]). However, there is still no clear evidence of a direct relationship between FGF-20 and the apoptosis mechanisms. For this reason, the lower number of dying cells in the presence of FGF-20 might as well result from an improved cell survival through other pathways.

The percentages of cells exhibiting cleaved caspase-3 at the time of fixation (21 days after starting the co-culture) were small. However, it has to be emphasized that detection of cleaved caspase-3 is limited to a number of hours, until the cells eventually lyse and disappear from the culture (Correia et al., [@B10]). In essence we are only providing a "snapshot" of the cells that are dying at a particular time point in the culture procedure. Therefore, these values can be seen to underestimate the protective effect of FGF-20, and do not reflect the cells that had died throughout the whole culture experiment, which lasted for 21 days. If the rate of cell death is similar over the whole 21-day culture period and dying/dead cells remain positive for cleaved caspase 3 during approximately 12 h, we can estimate a 52% reduction in cell death in the presence of FGF-20. The lower cell death in the FGF-20-treated cultures can result in a substantial increase in living TH-positive neurons. Unfortunately, we were not able to definitively determine if the dying neurons were dopaminergic. The identification of dying dopaminergic neurons in culture is not easily achieved, because dying cells downregulate cytosolic proteins such as TH (Burke, [@B6]). As a result, the fact that we did not detect cells immunopositive for both TH and cleaved caspase-3, does not clarify the issue of whether the cells positive for cell death markers were dopaminergic or not. Using for example a reporter gene coupled to TH and live cell imaging would be one method to address this issue systematically.

How Could FGF-20 Contribute to the Development of a Cell-Based Therapy for Parkinson\'S Disease?
================================================================================================

One of the major limitations in the development of a cell therapy for PD is that dopaminergic neurons survive poorly when transplanted (Ben-Hur et al., [@B2]; Brederlau et al., [@B4]; Park et al., [@B33]; Zeng et al., [@B54]). Therefore, the high yield of dopaminergic neurons obtained from hESCs in the presence of FGF-20 might provide a direct advantage for neural transplantation in PD. Previous studies showed that treatment of intrastriatal implants of embryonic mesencephalic tissue with neurotrophic factors, such as GDNF, BDNF, neurotrophin (NT)-4/5, NT-3, NTN, nerve growth factor (NGF), growth/differentiation factor (GDF)-5, insulin-like growth factor (IGF)-1, TGF-β, acidic FGF (aFGF) and basic FGF (bFGF), increases the survival rates of TH-positive neurons to approximately 30--35% (Brundin et al., [@B5]; Sortwell, [@B44]). Additionally, it affects the functional capacity of grafted dopaminergic neurons (Brundin et al., [@B5]; Giacobini et al., [@B14]; Haque et al., [@B20]; Rosenblad et al., [@B39], [@B38]; Sortwell, [@B44]; Sullivan et al., [@B45]; Yurek et al., [@B53]). In future studies we intend to investigate if FGF-20 can enhance neuronal survival of hESC-derived TH-positive neurons after grafting.

Numerous factors have been claimed to compromise the survival of mesencephalic dopaminergic neurons from human embryos during transplantation. Those factors include hypoxia, oxidative stress and trophic factor withdrawal. Similar factors are also likely to affect the survival of dopaminergic neurons derived from hESCs. Treatment with, e.g., antioxidants and trophic factors is beneficial to grafts of primary mesencephalic neurons (Brundin et al., [@B5]; Sortwell, [@B44]). Similar treatments may increase the survival of grafted hESC-derived dopamine neurons. Based on the published reports and on our own data (Correia et al., [@B10]; Murase and McKay, [@B28]; Ohmachi et al., [@B31], [@B30]), we hypothesize that FGF-20 could be used to improve graft survival by treating cells during/after implantation. In addition to the effects on hESC differentiation, it may also be added to the cell suspension during transplantation, improving the survival of the dopaminergic neuros *in vivo* (Figure [3](#F3){ref-type="fig"}). Another option would be to generate a viral vector expressing FGF-20 and co-injecting it with the transplant cells. It is also conceivable that a viral vector expressing FGF-20 could be tested in animal models of PD, with the ultimate aim of translating the technique to the clinic and reducing the progressive degeneration of dopamine neurons in PD. Obviously, safety aspects and potentially undesirable effects (e.g. inflammation, proliferation of mesenchymal cells etc) of long-term administration of FGF-20 to the brain must first be carefully explored.

![**Possible applications of FGF-20 in a cell-based therapy for Parkinson\'s disease**.](fnins-02-026-g003){#F3}

Conclusions
===========

We believe that in the future FGF-20 supplementation should be incorporated in the hESC-based *in vitro* differentiation protocols intent to derive the dopaminergic neurons. This adaptation will increase yield of large quantities of dopaminergic neurons with a classical *substantia nigra* phenotype from hESCs. In order to improve the survival of the hESC-derived dopaminergic neurons during transplantation, FGF-20 could also be added to the cell suspension during implantation. Further studies are needed to examine the survivability and functionality of the dopaminergic neurons derived from the hESCs in the presence of FGF-20, and also the trophic effect of FGF-20 in the implanted cells.
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